Detection of Acid-Labile Conjugates of Ketamine and Its Metabolites in Urine Samples Collected from Pub Participants

Journal of Analytical Toxicology

Volumn 28, Issue 3, 2004, Pages 181-186

  Lin, Huei R ^a   Lua, Ahai C ^a  

^a TZU CHI UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

DEHYDRONORKETAMINE; KETAMINE; NORKETAMINE; UNCLASSIFIED DRUG;

ACCURACY; ALKALINIZATION; ARTICLE; BIOTRANSFORMATION; DRUG ABUSE; DRUG DETERMINATION; GAS CHROMATOGRAPHY; HUMAN; HYDROLYSIS; MASS SPECTROMETRY; QUANTITATIVE ANALYSIS; URINALYSIS;

EID: 1842424846     PISSN: 01464760     EISSN: None     Source Type: Journal    
DOI: 10.1093/jat/28.3.181     Document Type: Article

References (24)

1. E.F. Domino, P. Chodoff, and G. Corssen. Pharmacologic effects of CI-581, a new dissociative anesthetic, in man. Clinical and Pharmaceutical Therapeutics 6: 279-291 (1965).
2. G.E. Morgan, Jr. and M.S. Mikhail. Clinical Anesthesiology, 2nd ed. Appleton-Lange, Stamford, CT, 1996, pp 141-143.
3. K.L.R. Jansen and M.R.C Psych. A review of the nonmedical use of ketamine: use, users and consequences. J. Psychoactive Drugs 32: 419-433 (2000).
4. J. Drefer and T. Honore. Phencyclidine analogues inhibit NMDA-stimulated GABA release from cultured cortex neurons. Eur. J. Pharmacol. 143: 287-290 (1987).
5. A. Anand, D.S. Charney, D.A. Oren, R.M. Berman, X. Hu, S.A. Cappiello, and J.H. Krystal. Attenuation of the neuropsychiatric effects of ketamine and lamotrigine: support of hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists. Arch. Gen. Psychiatry 57: 270-276 (2000).
6. K.L. Jansen. Transcendental explanation and near death experience. Lancet 337: 244 (1991).
7. R.C. Baselt and R.H. Cravey. Disposition of Toxic Drugs and Chemicals in Man, 4th ed. Chemical Toxicology Institute, Foster City, CA, 1995, pp 412-414.
8. 18F] fluorodeoxyglucose (FDG). Eur. Neuropsychopharmacol 7: 9-24 (1997).
9. S.N. Ahmed and L. Petchkovsky. Abuse of ketamine. Br. J. Psychiatry 137: 303 (1980).
10. J.R. Gill and M. Stajic. Ketamine in non-hospital and hospital deaths in New York City. J. Forensic Sci. 45: 655-658 (2000).
11. K.A. Moore, J. Sklerov, B. Levine, and A.J. Jacobs. Urine concentration of ketamine and norketamine following illegal consumption. J. Anal. Toxicol. 25: 583-588 (2001).
12. K.A. Moore, E.M. Kilbane, R. Jones, G.W. Kunsman, B. Levine, and M. Smith. Tissue distribution of ketamine in a mixed drug fatality. J. Forensic Sci. 42: 1183-1185 (1997).
13. M.M. Kochhar. The identification of ketamine and its metabolites in biological fluids by gas-chromatography-mass spectrometry. Clin. Toxicol. 11: 265-275 (1977).
14. S.A. Savchuk, E.S. Brodskii, B.A. Rudenko, A.A. Formanovskii, I.V. Mikhura, and N.A. Davydova. Determination of biotransformation products of the anesthetic ketamine by gas chromatography-mass spectrometry. J. Anal. Chem. 52: 1175-1186 (1997).
15. P. Kintz, P. Mangin, A.A. Lugnier, and A.J. Chaumont. The determination of ketamine in biological fluids. Cahier Anesthesiol. 38: 173-174 (1990).
16. R.U. Stiller, P.G. Dayton, J.M. Perel, and C.C. Hug. Gas chromatographic analysis of ketamine and norketamine in plasma and urine; nitrogen-sensitive detection. J. Chromatogr. 232: 305-314 (1982).
17. N. Feng, F.X. Vollenweider, E.I. Minder, K. Rentsch, T. Grampp, and D.J. Vonderschmitt. Development of a gas chromatography-mass spectrometry method for determination of ketamine in plasma and its application to human samples. Ther. Drug Monit. 17: 95-100 (1995).
18. Y.A. Blednov and V.J. Simpson. Gas chromatography-mass spectrometry assay for determination of ketamine in brain. J. Pharmacol. Toxicol. Methods 41: 91-95 (1999).
19. S.A. Savchuk, B.A. Rudenko, E.S. Brodskii, A.A. Formanovskii, V.V. Erofeev, E.V. Babanova, V.V. Chistyakov, M.L. Rabinovich, and O.A. Dolina. Application of gas chromatography with selective detection and gas chromatography-mass spectrometry to identifying ketamine metabolites and to examining the conjugation of ketamine and its metabolites in human and rat organism. J. Anal. Chem. 53: 583-589 (1998).
20. J.D. Adams, T.A. Baillie, A.J. Trevor, and N. Castagnoli. Studies on the biotransformation of ketamine. 1. Identification of metabolites produced in vitro from rat liver microsomal preparations. Biomed. Mass Spectrom. 8: 527-538 (1981).
21. P. Stenberg and J. Idvall. Does ketamine metabolite II exist in vivo? Br. J. Anes. 53: 778 (1981).
22. J. Wieber, R. Gugler, J.H. Hengstmann, and H.J. Dengler. Pharmacokinetics of ketamine in man. Anaesthesist 24: 260-263 (1975).
23. S.H.L. Chiu and S.E.W. Huskey. Species differences in N-glucuronidation. 1996 ASPET N-glucuronidation of xenobiotics symposium. Drug Metab. Dispos. 26: 838-847 (1998).
24. A. Hiller, N. Nguyen, C.P. Strassburg, Q. Li, H. Jainta, B. Pechstein, P. Ruus, J. Engel, R.H. Tukey, and T. Kronbach. Retigabine N-glucuronidation and its potential role in enterohepatic circulation. Drug Metab. Dispos. 27: 605-612 (1999).